KLRK1 and colorectal cancer: Four other clinical trials evaluated the treatment of NKG2D CAR T cells in patients with colorectal cancer (NCT03310008), AML (NCT03612739, NCT03466320), and multiple solid and hematological tumors (NCT03018405).